When (Not) to Stop a Clinical Trial for Benefit
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
cancer screening strategies in low-resource settings: clinical benefits and cost effectiveness. JAMA. 2001;285:3107-3115. 25. Crum CP. The beginning of the end for cervical cancer? N Engl J Med. 2002; 347:1703-1705. 26. Skjeldstad FE, Koustsky L; for theMerck Phase III HPV Vaccine Steering Com-mittee (FUTURE II). Phase III trial of prophylactic quadrivalent HPV 6, 11, 16, 18 L1 virus-like particle (VLP) vaccine: prevention of cervical intraepithelial neoplasia (CIN) 2/3 including adeno- and squamous-cell carcinoma in situ (CIS). Presented
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Contradicted and Initially Stronger Effects in Highly Cited Clinical Research
Ioannidis, J. P. A. (2005) · JAMA · doi:10.1001/jama.294.2.218 · Cited by 1,465
Moher, D., Schulz, K. F., Altman, D. G., & for the CONSORT Group* (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00011 · Cited by 1,426
Multiplicity in randomised trials II: subgroup and interim analyses
Schulz, K. F., & Grimes, D. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66516-6 · Cited by 357
A proposed charter for clinical trial data monitoring committees: helping them to do their job well
(2005) · The Lancet · doi:10.1016/s0140-6736(05)17965-3 · Cited by 324
When to stop a clinical trial.
Pocock, S. J. (1992) · BMJ · doi:10.1136/bmj.305.6847.235 · Cited by 255 · cited 1×
“The ethical dilemma is to safeguard the interests of patients randomized in the current trial while also protecting society from overzealous premature claims of treatment benefit.(11) For instance, if a trial is evaluating a treatment meant to be given long-term for conditions such as hypertension or chronic arthritis…”
BackgroundSelf-citationThe agonising negative trend in monitoring of clinical trials
DeMets, D. L., Pocock, S. J., & Julian, D. G. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03464-9 · Cited by 126
Self-citationSydes, M. R., Altman, D. G., Babikera, A. B., Parmar, M. K., Spiegelhalter, D. J., & DAMOCLES group (2004) · Clinical Trials · doi:10.1191/1740774504cn003oa · Cited by 49
Cited by
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationGRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
Colchicine in Patients with Chronic Coronary Disease
Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X.-F., Ireland, M. A., Lenderink, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021372 · Cited by 2,299
Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis
Mas, J.-L., Chatellier, G., Beyssen, B., Branchereau, A., Moulin, T., Becquemin, J.-P., Larrue, V., Lièvre, M., Leys, D., Bonneville, J.-F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061752 · Cited by 1,578
Bassler, D. (2010) · JAMA · doi:10.1001/jama.2010.310 · Cited by 611
Total Hip Arthroplasty or Hemiarthroplasty for Hip Fracture
The HEALTH Investigators (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1906190 · Cited by 517
Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis
Boulware, D. R., Meya, D. B., Muzoora, C., Rolfes, M. A., Huppler Hullsiek, K., Musubire, A., Taseera, K., Nabeta, H. W., Schutz, C., Williams, D. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312884 · Cited by 497
Adaptive design methods in clinical trials–a review
Chow, S.-C., & Chang, M. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-11 · Cited by 482
“There are common issues that affect a DMC's decision, such as short-term versus long-term treatment effects, early termination philosophies, response to early beneficial trends, response to early unfavorable trends, and response where there are no apparent trends [52,53].”
Adaptive increase in sample size when interim results are promising: a practical guide with examples
Mehta, C. R., & Pocock, S. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4102 · Cited by 367
Self-citationDe testimonio: on the evidence for decisions about the use of therapeutic interventions
Rawlins, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61930-3 · Cited by 362
Brocklehurst, P., Field, D., Greene, K., Juszczak, E., Keith, R., Kenyon, S., Linsell, L., Mabey, C., Newburn, M., Plachcinski, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30568-8 · Cited by 207
Ethical issues in stopping randomized trials early because of apparent benefit.
Mueller, P. S., Montori, V. M., Bassler, D., Koenig, B. A., & Guyatt, G. H. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00009 · Cited by 202
Hall, N. J., Pacilli, M., Eaton, S., Reblock, K., Gaines, B. A., Pastor, A., Langer, J. C., Koivusalo, A. I., Pakarinen, M. P., Stroedter, L., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60006-4 · Cited by 182
Schmidt, F., Kolle, K., Kreuder, K., Schnorbus, B., Wild, P., Hechtner, M., Binder, H., Gori, T., & Münzel, T. (2015) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0751-x · Cited by 180
“001 between visits [9, 10].”
An Introduction to Survival Statistics: Kaplan-Meier Analysis
N. Dudley, P., Wickham, P., & Coombs, M. (2016) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2016.7.1.8 · Cited by 168
“A predetermined stopping boundary is a method to determine if a study can be stopped early—for instance, when the primary outcome variable has been reached (Pocock, 2005).”
MethodSchottenfeld, R. S., Chawarski, M. C., & Mazlan, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60954-x · Cited by 99
Ebben, M. R., Narizhnaya, M., Segal, A. Z., Barone, D., & Krieger, A. C. (2014) · Sleep Medicine · doi:10.1016/j.sleep.2014.01.011 · Cited by 62
“01 based on Pocock’s recommendation [30] that reducing the chance of type I error to 1% (and establishing a Pocock boundary) sufficiently reduces the risk of incorrectly rejecting the null hypothesis when unplanned testing is performed.”
Background
Metadata
- Authors
- Pocock, S. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-11-02
- Volume
- 294
- Issue
- 17
- Pages
- 2228
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2053830943
- Cited by
- 163
- References
- 9
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.